ASCO 2025:
Promizing CD206/CD209/IL6 decrease in TME by ancentrally active antagonist of C/EBPbleading to positive trends in PFS and OS in GBM patients; based on solid non-clinical evidence (PI/II: NCT04478279)
Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization.
Fabio Massaiti Iwamoto, Osama Al Dalahmah, Jim Rotolo, Franco Abbate, Clara Levrero, Joyce Gakuria, Robin Arthur Buerki, Abi Vainstein Haras; Columbia University Irving Medical Center, New York, NY; Sapience Therapeutics, Inc., Tarrytown, NY; Columbia University Medical Center, New York, NY; Northwestern Medicine Cancer Center, Warrenville, IL
